7th Oct 2025 09:22
(Alliance News) - Oxford BioMedica PLC on Tuesday said it has closed a deal to acquire a cell and gene therapy viral vector manufacturing facility in Durham, North Carolina.
The Oxford, England-based gene and cell therapy developer said the asset purchase deal was signed with RTP Operating LLC, a subsidiary of National Resilience Holdco Inc, for a total consideration of USD4.5 million paid by Oxford BioMedica.
The acquisition expands Oxford BioMedica's manufacturing capabilities in the US up to commercial-scale, increasing good manufacturing practice capacity and enhancing services to its North American clients.
The site in North Carolina's Research Triangle Park includes two operational GMP drug substance suites, a fill-finish suite, a further expansion-ready GMP suite, and on-site QC labs and warehousing.
The purchase allows the company to support late-stage programmes and commercial launches from the US, particularly in the adeno-associated virus, or AAV, field.
Following the acquisition, Oxford BioMedica's existing Bedford, Massachusetts site will remain "an AAV centre of excellence for process and analytical development", focusing on early-stage development activities. The North Carolina site is set to become "a hub" for clinical and commercial activities, the company said.
"This acquisition is a major milestone in OXB's evolution as a global, innovation-led CDMO partner of choice. The FDA approved facility in North Carolina adds commercial-scale US manufacturing capabilities, accelerating OXB's ability to meet growing demand from existing clients while supporting new business opportunities," said Oxford BioMedica Chief Executive Officer Frank Mathias.
"It significantly expands our footprint in the world's largest cell and gene therapy market and enhances our ability to support clients globally across all major viral vector types and stages of development, particularly those in the AAV field. By expanding our capabilities in the US, we're executing on our growth strategy and unlocking long-term value for both clients and shareholders."
Key functions at the site are expected to be operational by the first quarter of 2026. Oxford BioMedica expects to realise a single-digit gain in 2025 as a result of the acquisition, which is anticipated to broadly offset any associated costs for the new site in 2025.
The company intends to hire additional operating staff at the acquired site, and will also make strategic investments in its existing sites to meet "growing" client demand.
Oxford BioMedica on Tuesday reiterated its existing near and medium-term financial guidance. The firm expects to deliver above-market growth, achieve earnings before interest, tax, depreciation and amortisation profitability from financial 2025 on a constant currency basis, and strengthen its "competitive" position in the global viral vector market.
Shares in Oxford BioMedica were down 0.5% at 633.61 pence in London on Tuesday morning. The stock has risen 66% over the past year.
By Emily Parsons, Alliance News reporter
Comments and questions to [email protected]
Copyright 2025 Alliance News Ltd. All Rights Reserved.
Related Shares:
Oxford Biomedica